Original Article

Stress Ulcer Prophylaxis in Hospitalized Patients, Subsequent Use in Primary Care, and Physicians’ Opinions About Acid-Suppressive Therapy

Authors: Muhammad Riaz, MD, MS, Susan Hughes, MS, Ivan A. Gomez, MD, MS, Roger B. Mortimer, MD

Abstract

Objectives: Stress ulcer prophylaxis (SUP) is not indicated in most hospitalized patients. This study determined the prevalence of the use of proton pump inhibitors (PPI) and histamine receptor 2 blockers (H2B) in hospitalized patients, continued PPI/H2B use after discharge, and physicians’ opinions about SUP.

Methods: A retrospective electronic chart review, as well as a national survey of residents and faculty in primary care residency programs to determine the appropriateness of SUP.

Results: Of 753 charts reviewed, 332 hospitalized patients with outpatient follow-up were included; 303 of them had either PPI or H2B ordered during hospitalization, but only 120 patients had an indication for SUP. Stepwise logistic regression results showed patients with a history of PPI/H2B use were 16.6 times more likely to receive SUP (odds ratio 16.6; 95% confidence interval 2.2–124.7). In addition, a PPI/H2B indication also significantly predicted SUP use (odds ratio 5.1; 95% confidence interval 1.2–22.2). A total of 171 completed surveys were received: 73% residents and 27% faculty. Only 24% reported being aware of SUP guidelines; 17% reported using electronic health record order set suggestions for SUP.

Conclusions: More than 90% of hospitalized patients received SUP; less than half of them had an indication for needing SUP. A large number of patients discharged on PPI/H2B continued to receive it in the outpatient setting at 6 months follow-up. Only 24% of physicians reported using SUP based on guidelines. Physician education and evidence-based validation of electronic health record order sets are potential areas for improvement.

 

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Skillman JJ, Bushnell LS, Goldman H, et al. Respiratory failure, hypotension, sepsis, and jaundice. A clinical syndrome associated with lethal hemorrhage from acute stress ulceration of the stomach. Am J Surg 1969;117:523-5302.
 
2. Harris SK, Bone RC, Ruth WE. Gastrointestinal hemorrhage in patients in a respiratory intensive care unit. Chest 1977;72:301-3042.
 
3. Cook D, Heyland D, Griffith L, et al. Risk factors for clinically important upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. Crit Care Med 1999;27:2812-28172.
 
4. Cook DJ, Fuller HD, Guyatt GH, et al. Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group. N Engl J Med 1994;330:377-3812.
 
5. Cook DJ, Griffith LE, Walter SD, et al. The attributable mortality and length of intensive care unit stay of clinically important gastrointestinal bleeding in critically ill patients. Crit Care 2001;5:368-3752.
 
6. Choung RS, Talley NJ. Epidemiology and clinical presentation of stress-related peptic damage and chronic peptic ulcer. Curr Mol Med 2008;8:253-2572.
 
7. Faisy C, Guerot E, Diehl JL, et al. Clinically significant gastrointestinal bleeding in critically ill patients with and without stress-ulcer prophylaxis. Intensive Care Med 2003;29:1306-13132.
 
8. Krag M, Perner A, Wetterslev J, et al. Stress ulcer prophylaxis in the intensive care unit: is it indicated? A topical systematic review. Acta Anaesthesiol Scand 2013;57:835-8472.
 
9. Gupta R, Garg P, Kottoor R, et al. Overuse of acid suppression therapy in hospitalized patients. South Med J 2010;103:207-2112.
 
10. Nardino RJ, Vender RJ, Herbert PN. Overuse of acid-suppressive therapy in hospitalized patients. Am J Gastroenterol 2000;95:3118-31222.
 
11. Wohlt PD, Hansen LA, Fish JT. Inappropriate continuation of stress ulcer prophylactic therapy after discharge. Ann Pharmacother 2007;41:1611-16162.
 
12. Zink DA, Pohlman M, Barnes M, et al. Long-term use of acid suppression started inappropriately during hospitalization. Aliment Pharmacol Ther 2005;21:1203-12092.
 
13. Ahrens D, Behrens G, Himmel W, et al. Appropriateness of proton pump inhibitor recommendations at hospital discharge and continuation in primary care. Int J Clin Pract 2012;66:767-7732.
 
14. Grant K, Al-Adhami N, Tordoff J, et al. Continuation of proton pump inhibitors from hospital to community. Pharm World Sci 2006;28:189-1932.
 
15. ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998. Am J Health Syst Pharm 1999;56:347-3792.
 
16. Scagliarini R, Magnani E, Pratico A, et al. Inadequate use of acidsuppressive therapy in hospitalized patients and its implications for general practice. Dig Dis Sci 2005;50:2307-23112.
 
17. Grube RR, May DB. Stress ulcer prophylaxis in hospitalized patients not in intensive care units. Am J Health Syst Pharm 2007;64:1396-14002.
 
18. Hussain S, Stefan M, Visintainer P, et al. Why do physicians prescribe stress ulcer prophylaxis to general medicine patients? South Med J 2010;103:1103-11102.
 
19. Koczka CP, Geraldino-Pardilla LB, Goodman AJ. Physicians’ opinions of stress ulcer prophylaxis: survey results from a large urban medical center. Dig Dis Sci 2013;58:777-7812.
 
20. Liberman JD, Whelan CT. Brief report: reducing inappropriate usage of stress ulcer prophylaxis among internal medicine residents. A practice-based educational intervention. J Gen Intern Med 2006;21:498-5002.
 
21. Zeigler AJ, McAllen KJ, Slot MG, et al. Medication reconciliation effect on prolonged inpatient stress ulcer prophylaxis. Ann Pharmacother 2008;42:940-9462.
 
22. Gupta R, Marshall J, Munoz JC, et al. Decreased acid suppression therapy overuse after education and medication reconciliation. Int J Clin Pract 2013;67:60-652.
 
23. Farley KJ, Barned KL, Crozier TM. Inappropriate continuation of stress ulcer prophylaxis beyond the intensive care setting. Crit Care Resusc 2013;15:147-1512.
 
24. Altschuler J, Margolius D, Bodenheimer T, et al. Estimating a reasonable patient panel size for primary care physicians with team-based task delegation. Ann Fam Med 2012;10:396-4002.
 
25. Thomas L, Culley EJ, Gladowski P, et al. Longitudinal analysis of the costs associated with inpatient initiation and subsequent outpatient continuation of proton pump inhibitor therapy for stress ulcer prophylaxis in a large managed care organization. J Manag Care Pharm 2010;16:122-1292.
 
26. Howell MD, Novack V, Grgurich P, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 2010;170:784-7902.
 
27. Lewis JR, Barre D, Zhu K, et al. Long-term proton pump inhibitor therapy and falls and fractures in elderly women: a prospective cohort study. J Bone Miner Res 2014;29:2489-24972.
 
28. Ngamruengphong S, Leontiadis GI, Radhi S, et al. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol 2011;106:1209-12192.
 
29. Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006;296:2947-29532.
 
30. Linsky A, Gupta K, Lawler EV, et al. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med 2010;170: 772-7782.
 
31. Miano TA, Reichert MG, Houle TT, et al. Nosocomial pneumonia risk and stress ulcer prophylaxis: a comparison of pantoprazole vs ranitidine in cardiothoracic surgery patients. Chest 2009;136:440-4472.
 
32. Barkun AN, Adam V, Martel M, et al. Cost-effectiveness analysis: stress ulcer bleeding prophylaxis with proton pump inhibitors, H2 receptor antagonists. Value Health 2013;16:14-222.
 
33. MacLaren R, Campbell J. Cost-effectiveness of histamine receptor-2 antagonist versus proton pump inhibitor for stress ulcer prophylaxis in critically ill patients. Crit Care Med 2014;42:809-8152.
 
34. Preslaski CR, Mueller SW, Kiser TH, et al. A survey of prescriber perceptions about the prevention of stress-related mucosal bleeding in the intensive care unit. J Clin Pharm Ther 2014;39:658-6622.
 
35. Tasaka CL, Burg C, VanOsdol SJ, et al. An interprofessional approach to reducing the overutilization of stress ulcer prophylaxis in adult medical and surgical intensive care units. Ann Pharmacother 2014;48:462-469.